We describe the thrombophilic and clinical characteristics of a group of patients who suffered venous thrombosis (VT) ( n = 36) and ischemic stroke ( n = 8) while taking oral contraceptives (OC). Our purpose is to ascertain whether there are differences between users of second and third generation progestogen and to investigate the influence of concurrent congenital and acquired risk factors (other than OC) on the onset of the thrombosis. The group of patients included 36 women with VT and eight with ischemic stroke. The patients' recognized predisposing factors were recorded. We also considered age, length of time on OC, types of OC, rethrombosis, family history of VT, and the presence of thrombophilic genetic defects. In the group of patients with VT, 54% were treated with second generation OC ( n = 23), and 30% ( n = 11) were treated with third generation OC. We found no significant statistical differences with respect to age and length of time on OC between the two types of OC. The prevalence of genetic defects in these patients&mdash;factor V (FV) Leiden, prothrombin G20210A mutation and protein S deficiency&mdash;was 19% ( n = 7), 17% ( n = 6), and 8% ( n = 3) respectively. We observed the shortest time lapse between initiating OC and the first thrombotic event in carriers of FV Leiden and in patients with combined defects, but the differences were not significant. In patients with ischemic stroke, 50% were treated with second generation OC and 50% were treated with third generation OC. Prothrombin G20210A mutation was detected in two patients. In both patients,the stroke occurred earlier than in the rest of the patients, but these differences were not statistically significant. With respect to preventing thrombotic events in these patients, our data suggest that OC therapy should be avoided in patients with a previous history of thrombosis and in patients with an evident thrombotic tendency in the family. In patients in whom the family history of thrombosis is not very evident, it would be recommended to screen for FV Leiden, prothrombin G20210A mutation, and protein S, and to rule out OC if the patient does in fact have one of these risk factors. Moreover, if a patient develops a thrombotic complication while taking OC, an evaluation to search for a thrombophilic defect is warranted, and at the same time, alternative methods of contraception should be considered.
Summary: We describe the thrombophilic and clinical characteristics of a group of patients who suffered venous thrombosis (VT) ( n = 36) and ischemic stroke ( n = 8) while taking oral contraceptives (OC) . Our purpose is to ascertain whether there are differences between users of second and third generation progestogen and to investigate the influence of concurrent congenital and acquired risk factors (other than OC) on the onset of the thrombosis. The group of patients included 36 women with VT and eight with ischemic stroke. The patients' recognized predisposing factors were recorded. We also considered age, length of time on OC, types of OC, rethrombosis, family history of VT, and the presence of thrombophilic genetic defects. In the group of patients with VT, 54% were treated with second generation OC ( n = 23), and 30% ( n = 11) were treated with third generation OC. We found no significant statistical differences with respect to age and length of time on OC between the two types of OC. The prevalence of genetic defects in these patients&mdash;factor V (FV) Leiden, prothrombin G20210A mutation and protein S deficiency&mdash;was 19% ( n = 7), 17% ( n = 6), and 8% ( n = 3) respectively. We observed the shortest time lapse between initiating OC and the first thrombotic event in carriers of FV Leiden and in patients with combined defects, but the differences were not significant. In patients with ischemic stroke, 50% were treated with second generation OC and 50% were treated with third generation OC. Prothrombin G20210A mutation was detected in two patients. In both patients,the stroke occurred earlier than in the rest of the patients, but these differences were not statistically significant. With respect to preventing thrombotic events in these patients, our data suggest that OC therapy should be avoided in patients with a previous history of thrombosis and in patients with an evident thrombotic tendency in the family. In patients in whom the family history of thrombosis is not very evident, it would be recommended to screen for FV Leiden, prothrombin G20210A mutation, and protein S, and to rule out OC if the patient does in fact have one of these risk factors. Moreover, if a patient develops a thrombotic complication while taking OC, an evaluation to search for a thrombophilic defect is warranted, and at the same time, alternative methods of contraception should be considered. Key Words: Thrombosis&mdash;Oral Contraceptives&mdash; Venous Thrombois&mdash;Ischemic Stroke&mdash;Thrombosis Risk Factors.
Oral contraceptives (OC) are one of the most widely used medications in the healthy population worldwide.
The use of OC has been associated with increased risk of venous and arterial thrombosis (1-10), especially myocardial infarction (2, 8, (11) (12) (13) , ischemic stroke (14-16), cerebral sinus thrombosis (17, 18) and venous thromboembolism (3, 4, 7, 9, 10, 19, 20) . Hemorrhagic stroke (21, 22) and subarachnoid hemorrhage (23, 24) are also reported to be associated with their use.
The increased incidence of thrombovascular disease in women taking OC may be linked to either the increase in the levels of fibrinogen, factor X, prothrombin, factor VII, and factor VIII (25) (26) (27) (28) (29) (30) , or the decrease in protein S, protein C and antithrombin (31) (32) (33) .
Until recently, it was believed that the newer proges-togens in the third generation OCs would reduce the risk of arterial thrombosis because of their lower adverse impact on carbohydrate and lipoprotein metabolism (34, 35) . However, several studies (5, 8, (36) (37) (38) (39) provide reasonable evidence that users of third generation OC have a higher risk of venous thromboembolic disease than do users of the second generation type. Moreover, within the third generation progestogens, desogestrel seems to have a stronger thrombotic effect than gestodene (40) (41) (42) (43) .
Recently, new congenital factors such as factor V (FV) Leiden (44) and prothrombin G20210A mutation (45), associated with an increased risk of venous thrombosis (45) (46) (47) (48) , have been found, and the evidence indicates that OC acts synergistically with them to promote thrombotic events (49) (50) (51) (52) (53) (54) . However, the clinical circumstances involved in the thrombotic event in these patients have not been assessed thoroughly. The present study evaluates some aspects of the clinical situation linked to thrombotic events in 36 women with venous thrombosis (VT) and in eight women with ischemic stroke, all of whom were taking OC when the thrombosis occurred.
From our results, we have tried to establish whether there are differences between users of pills with second and third generation progestogens and to investigate the interaction of concurrent congenital or acquired risk factors (other than OC) on the onset of the thrombosis.
MATERIAL AND METHODS

Clinical group
The patient group included 36 women with confirmed diagnoses of VT and eight women who had had an episode of ischemic stroke. In all cases, the patients' recognized predisposing factors were recorded. Objective diagnostic procedures of the thrombosis were performed in all the patients. Vein thrombosis of the upper and lower extremities was diagnosed using ultrasonography or venography; pulmonary embolism, by ventilationperfusion lung scanning or pulmonary angiography; retinal venous thrombosis, by ophthalmoscopic examination ; mesenteric thrombosis, as a surgical finding, and cerebral venous thrombosis, by magnetic resonance imaging angiography. Moreover, we considered patient age, length of time taking OC (in months), types of OC used, rethrombosis, and possible previous thrombotic situations. The patients were asked about any family history of venous thromboembolism. Patients were considered to have a family history of thrombosis if one of their first (patient's parents or siblings) or second degree relatives (aunts, uncles, or grandparents) had had at least one VT. In the ischemic stroke group, the patients were interviewed about the presence of hypertension, diabetes, heart diseases, hyperlipidemia, migraine headaches, and smoking habits.
The presence of prothrombin G20210A and FV Leiden mutations, and the levels of antithrombin, heparin cofactor II, protein C, protein S, plasminogen activity, and anticardiolipin antibodies were evaluated more than six months after the occurrence of the last thrombotic event.
The family members were studied when at least one of the genetic thrombotic risk factors was detected in the propositus. Informed consent to participate in the study was obtained from all the patients.
Laboratory methods
Antithrombin antigen was measured by radial immunodiffusion. The plate contained monospecific antiserum to human antithrombin in an agarose gel layer (Behringwerke AG, Marburg, Germany). Anti-Xa activity was measured in the presence of heparin using the Coamatic Antithrombin Kit (Chromogenix AB, M61ndal, Sweden), and the assay was performed on an ACL 7000 autoanalyser (Instrumentation Laboratory, Milano, Italy). Heparin cofactor II (HCII) activity was determined quantita-tively (55) , using the Stachrom HCII assay (Diagnostica Stago, Asnieres, France). Heparin cofactor II antigen was measured using an enzyme-linked immunosorbent assay (ELISA, Enzyme Research Laboratories Ltd, Swansea, UK). Plasminogen activity was analyzed using Coamate Plasminogen (Chromogenix, M61ndal, Sweden). Protein C activity was analyzed using Coamate PC (Chromogenix, Mblndal, Sweden). Total protein S and free protein S was measured using a one-step enzyme immunoassay (Diagnostica Stago, Asnieres, France). Protein S activity was measured using the IL TestTM (Instrumentation Laboratory, Milano, Italy). The modified antigen-presenting cell (APC)-resistance assay was performed using previous dilution of the patient's plasma with factor V-depleted plasma, as previously reported (56) . The anticardiolipin (aCL) titer and IgG and IgM isotypes were analyzed using an ELISA (Chesire Diagnostic Ltd, Chester, England).
DNA was extracted from whole blood samples using the Genomic Purification System (Promega, Madison, USA) following the manufacturer's protocol. The FV Leiden mutation was studied using polymerase chain reaction (PCR) amplification and restriction analysis of a fragment of factor V DNA, following the method described by Gandrille et al. (57) . The prothrombin gene G20210A variant was detected using the PCR technique described previously (45) , followed by Hind III endonuclease digestion to reveal the G to A substitution in the prothrombin gene at position 20210.
Statistical analyses
All the assays were performed using the statistical package SPSS Release 6.0 for Windows (SPSS Inc, Chicago). Levels of significance between the two groups were determined by the Student t-test. Values of P < 0.05 were considered to be significant.
RESULTS
The clinical characteristics of the patients with VT are shown in Table 1 . A total of 64% of the patients were using second generation OC (n = 23) and 30% (n = 11) were using third generation OC. Two other patients used progestogen-only pills. Sixteen of the patients showed thrombophilic defects (44%).
Rethrombosis was found in four patients ( 11 %) . Patient 5, a carrier of FV Leiden and protein C deficiency, suffered two new events 5 and 7 years after the original episode (Budd-Chiari syndrome and VT in the lower limbs, both spontaneous). In the 13th patient, a carrier of FV Leiden and prothrombin G20210A mutation, the second thrombosis occurred 1 month after the first, but this patient had not been warned against taking OC and therefore had continued with this medication. In the 19th patient, the second thrombosis occurred 3 months after sus- pending treatment with acenocoumarol, and the third occurred the following year, coinciding with pregnancy. The patient was not receiving therapeutic doses of anticoagulants. The 28th patient had a new, spontaneous VT in the lower limbs 1 year after the initial event. Previous situations involving thrombotic risk, but not linked to an actual thrombotic event, were present in 13 patients (36%) (four patients had pregnancies; four had had surgery ; two had had sprains; and three had used OC previously). Of these, two had used second generation OC, though at present they are users of third generation, and one had taken second generation OC with ethinylestradiol 50 (EE50) pLg for 3 years and at present still uses second generation OC. However, none of the 13 patients had suffered thrombotic events previously. Postthrombotic syndrome was present in six patients (17%).
The patients' clinical characteristics in relation to second and third generation OC can be observed in Table 2 . We found no statistically significant differences between the parameters in terms of the type of OC used. Three Table 3 . A total of 19% of the patients (n = 7) showed the FV Leiden mutation; of these, 11 % (n = 4) had only this defect, and in 8% (n = 3), this disorder combined with another thrombophilic defect. A total of 17% was found to be heterozygous carriers of the prothrombin G20210A variant (n = 6); 14% (n = 5) had only this defect, and 3% (n -1) combined this disorder with other thrombophilic defects. Other single genetic defects were found in one patient (3%) with the heparin cofactor II deficiency, associated with an increased level of anticardiolipin (61 maximum permissible level [MPL]; normal range, 3-13 MPL), and in two patients (5.5%) with protein S deficiency. Combined genetic thrombophilic defects were observed in four patients: prothrombin 20210G/A plus FV Leiden (n = 1); FV Leiden plus protein C deficiency (n = 1); FV Leiden plus protein S deficiency (n = 1); and deficiency of antithrombin III plus heparin cofactor II deficiency (n = 1 ).
The clinical characteristics of the patients carrying genetic defects are given in Table 4 . We observed that the time elapsing between starting OC and the thrombosis was shorter in carriers of FV Leiden and in patients with combined defects, but the differences are not significant.
With respect to age at the time of thrombosis, we found no significant differences. Circumstantial factors other than OC are present in 31 % and 30% of the patients with and without thrombophilic defects, respectively.
The clinical characteristics of the patients with ischemic stroke are shown in Table 5 . The mean age at the time of the thrombotic episode was 32.4 ± 7.7 years, being 33.5 ± 4.7 years for users of third generation OC, and 31.2 ± 9.2 years for users of second generation OC. Again, the differences were not significant. Patients using second generation OC represented 50% (n = 4) and patients using third generation OC, 50% (n = 4) (one using desogestrel and three using gestodene). The length of time of OC use before the thrombotic event was 37.2 ± 33.6 months; the averages were 40.0 ± 34.4 months and 27.7 ± 45.5 months for users of second and third generation OC, respectively. The differences were not statistically significant. The prothrombin G20210A mutation was found in two patients (25%). The thrombotic event occurred earlier in patients with thrombophilia (27.5 ± 1.5 months, versus 34.0 ± 8.3 months, respectively), but the differences were not statistically significant. Seven out of eight patients had other circumstantial thrombotic risk factors (two patients had dyslipemia; one had a smoking habit plus high levels of triglycerides; one had hypertension; and three had migraine headaches, two of which were associated with smoking habits). Only one (12.5%) patient did not have thrombophilic defects or circumstantial thrombotic risk factors other than OC. Only one patient with a thrombophilic defect had a family history of thrombosis (12%; her father and sister had both had strokes). One patient who did not have a thrombophilic defect had a new ischemic stroke after ending OC treatment; the other seven patients did not suffer rethrombosis and survived with no neurological deficit.
DISCUSSION .
In this report, we describe the thrombophilic and clinical characteristics of a group of 44 patients on OC who had venous and arterial thrombosis. All the patients had (3, third generation; 2, second generation); AHT, arterial hypertension; G20210A, prothrombin G20210A. the thrombotic event after beginning to take OC, regardless of whether they had other circumstantial thrombotic risk factors.
Of the congenital thrombotic risk factors observed in the 36 patients with VT, FV Leiden was the most prevalent (19%), followed by the prothrombin G20210A mutation (17%). This finding is consistent with the fact that OC substantially increases the possibility of thrombotic phenomena in women carrying one of these hereditary thrombophilic defects. Martinelli (54) found that the risk of thrombosis increased to 16.3 and 20.0 respectively when women with prothrombin G20210A mutation or FV Leiden used OC, and in a recent study (58) in our laboratory we also found that the risk of thrombosis in women using OC increases far more when the women are carriers of FV Leiden and the prothrombin G20210A mutation. We also observed a high incidence of protein S deficiency 8.3% (n = 3). The literature contains few studies describing an association between thrombosis and the use of OC and protein S deficiency (31 ) , probably because of the low prevalence of this deficiency in the normal population (59, 60) . Some authors (61) believe that there is no evidence of an excessive thrombotic risk caused by OC intake by females who are deficient in protein S, but our results suggest that the combination of protein S deficiency and OC leads to increased thrombotic risk. Another striking finding in our study is that in 39% of our patients with VT, the thrombotic event occurred when OC was the only risk factor present. Moreover, in 57% of our patients who were carriers for FV Leiden and in 83% of our patients who were carriers for prothrombin G20210A, OC was the only circumstantial risk factor. It must also be noted that in our study, only 9% of the women using third generation OC had other circumstantial risk factors, as opposed to 43% of the women using second generation OC. In addition, the prevalence of thrombophilic defects was higher (54% versus 39%) in the group of patients who were taking second generation OC. These results may mean that the risk of VT is higher in users of third generation OC than among users of second generation OC.
With respect to the length of time on OC, it is important to note that although in some women the thrombotic event occurred almost immediately after starting OC treatment (Table 1) , the average in our patients places the occurrence of thrombosis at 18.6 months after beginning OC. This time was shorter among patients taking third generation OC (Table 2 ), which may reflect increased thrombotic risk with this treatment. In our opinion, the most significant finding related to the timing of the thrombotic event is that in women who were taking OC and were carriers for FV Leiden, thrombosis occurred 6.2 ± 4.0 months after starting with OC, a much shorter period than in the patients who were carriers for the prothrombin G20210A mutation (17.2 ± 12.7 months) or among those who had a congenital risk factor (17.2 ± 23.3 months) or who did not have one (19.3 ± 27.8 months).
The prevalence of rethrombosis among our patients in the 7 years after discontinuation of OC use was 11 %. The fact that of this 11%, only 8.3% of patients had an additional thrombotic risk factor suggests that the presence of these risk factors hardly increases the incidence of rethrombosis if women stop of taking OC after the first thrombotic event. This low incidence argues against initiating long term anticoagulation therapy in women who have had thrombosis while taking OC, if they have no other risk factors.
The percentage of women with postphlebitic syndrome was 17%, which is very similar to that reported in studies involving a large number of patients with VT (62) . On the other hand, in our patients no relationship was found between the postphlebitic syndrome and the earlier presence of thrombotic risk factors other than OC. These data seem to indicate that OC is not a risk factor for this syndrome.
Although few of the women (n = 8) in our study suffered strokes, it is important to note that this type of thrombosis occurred earlier in patients using third generation OC (27.7 ± 45.5 months) than in those using second generation OC (40.0 ± 34.4 months). It must also be pointed out that only five of these eight women had associated risk factors, which suggests that the risk involved in using OC may be reduced by reducing the associated risk factors.
In summary, although the percentage of women taking OC who develop thrombosis is not very high, the fact that they are fairly young women does increase the relevance. It is this finding that is behind the controversy about whether or not a screening for congenital thrombotic risk factors should be carried out before initiating OC. In our opinion, because FV Leiden shows a high prevalence in the normal population (3-5%) and because it can be detected using an easy, economical coagulation test (56) , it would be worthwhile conducting an APC resistance (APCr) screening before a patient starts to use OC. However, this screening should not encompass the prothrombin G20210A mutation, for this requires expensive, time-consuming genetic testing. We could, in general, conclude that patients who have a history of thrombosis or whose family shows an evident thrombotic tendency should probably not take OC. In those cases in which there is no clear family history of thrombosis, screening for FV Leiden, prothrombin G20210A mutation, and protein S would be preceptive, and OC should be ruled out if the patient tests positive for at least one of these factors. Nevertheless, if a patient develops a thrombotic complication while taking OC, an evaluation to search for a thrombophilic defect is warranted and alternative methods of contraception should be considered.
